HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1

Life Sciences

Volumn 79, Issue 14, 2006, Pages 1380-1390

  Morikawa Futamatsu, Kino ^a   Adachi, Susumu ^a   Maejima, Yasuhiro ^a   Tamamori Adachi, Mimi ^a   Suzuki, Jun ichi ^a   Kitajima, Shigetaka ^a   Ito, Hiroshi ^b   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin; Hypertrophy; Statins

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADENOVIRUS VECTOR; ANGIOTENSIN II; CYCLIN D1; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUCINE; RECOMBINANT DNA; RHO KINASE; RHO KINASE INHIBITOR; TRITIUM;

AMINO ACID TRANSPORT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL SIZE; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME ACTIVATION; GENE OVEREXPRESSION; GENE TRANSFER; HEART VENTRICLE HYPERTROPHY; HYPERTROPHY; INHIBITION KINETICS; MALE; NEWBORN; NONHUMAN; PROTEIN SYNTHESIS; RAT; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE INFECTIONS; AMIDES; ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; CELLS, CULTURED; CYCLIN D1; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; FATTY ACIDS, MONOUNSATURATED; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOBLOTTING; INDOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUCINE; MALE; MEVALONIC ACID; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

RATTUS NORVEGICUS;

EID: 33747033675     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.04.005     Document Type: Article

References (30)

1. Adachi S., Ito H., Tamamori-Adachi M., Ono Y., Nozato T., Abe S., Ikeda M., Marumo F., and Hiroe M. Cyclin A/cdk2 activation is involved in hypoxia-induced apoptosis in cardiomyocytes. Circulation Research 88 4 (2001) 408-414
2. Aoki H., Izumo S., and Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circulation Research 82 6 (1998) 666-676
3. Bellosta S., Bernini F., Ferri N., Quarato P., Canavesi M., Arnaboldi L., Fumagalli R., Paoletti R., and Corsini A. Direct vascular effects of HMG-CoA reductase inhibitors. Atherosclerosis 137 (1998) S101-S109 (Suppl)
4. Clerk A., and Sugden P.H. Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circulation Research 86 10 (2000) 1019-1023
5. Corsini A., Pazzucconi F., Arnaboldi L., Pfister P., Fumagalli R., Paoletti R., and Sirtori C.R. Direct effects of statins on the vascular wall. Journal of Cardiovascular Pharmacology 31 5 (1998) 773-778
6. Esposito G., Rapacciuolo A., Naga Prasad S.V., Takaoka H., Thomas S.A., Koch W.J., and Rockman H.A. Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105 1 (2002) 85-92
7. Higashi M., Shimokawa H., Hattori T., Hiroki J., Mukai Y., Morikawa K., Ichiki T., Takahashi S., and Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circulation Research 93 8 (2003) 767-775
8. Indolfi C., Di Lorenzo E., Perrino C., Stingone A.M., Curcio A., Torella D., Cittadini A., Cardone L., Coppola C., Cavuto L., Arcucci O., Sacca L., Avvedimento E.V., and Chiariello M. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 106 16 (2002) 2118-2124
9. Kaneta S., Satoh K., Kano S., Kanda M., and Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 170 2 (2003) 237-243
10. Kinoshita A., Wanibuchi H., Imaoka S., Ogawa M., Masuda C., Morimura K., Funae Y., and Fukushima S. Formation of 8-hydroxydeoxyguanosine and cell-cycle arrest in the rat liver via generation of oxidative stress by phenobarbital: association with expression profiles of p21(WAF1/Cip1), cyclin D1 and Ogg1. Carcinogenesis 23 2 (2002) 341-349
11. Kozar K., Ciemerych M.A., Rebel V.I., Shigematsu H., Zagozdzon A., Sicinska E., Geng Y., Yu Q., Bhattacharya S., Bronson R.T., Akashi K., and Sicinski P. Mouse development and cell proliferation in the absence of D-cyclins. Cell 118 4 (2004) 477-491
12. Kranenburg O., van der Eb A.J., and Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO Journal 15 1 (1996) 46-54
13. Laufs U., Marra D., Node K., and Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). Journal of Biological Chemistry 274 31 (1999) 21926-21931
14. Maejima Y., Adachi S., Ito H., Nobori K., Tamamori-Adachi M., and Isobe M. Nitric oxide inhibits ischemia/reperfusion-induced myocardial apoptosis by modulating cyclin A-associated kinase activity. Cardiovascular Research 59 2 (2003) 308-320
15. Massy Z.A., Keane W.F., and Kasiske B.L. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?. Lancet 347 8994 (1996) 102-103
16. Moh M.C., Lee L.H., Yang X., and Shen S. HEPN1, a novel gene that is frequently down-regulated in hepatocellular carcinoma, suppresses cell growth and induces apoptosis in HepG2 cells. Journal of Hepatology 39 4 (2003) 580-586
17. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., and Loh D.Y. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85 5 (1996) 707-720
18. Nishikimi T., Tadokoro K., Wang X., Mori Y., Asakawa H., Akimoto K., Yoshihara F., Horio T., Minamino N., and Matsuoka H. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. European Journal of Pharmacology 453 2-3 (2002) 175-181
19. Nozato T., Ito H., Tamamori M., Adachi S., Abe S., Marumo F., and Hiroe M. G1 cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II. Japanese Circulation Journal 64 8 (2000) 595-601
20. Oda H., Kasiske B.L., O'Donnell M.P., and Keane W.F. Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. Kidney International. Supplement 71 (1999) S202-S205
21. Oi S., Haneda T., Osaki J., Kashiwagi Y., Nakamura Y., Kawabe J., and Kikuchi K. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. European Journal of Pharmacology 376 1-2 (1999) 139-148
22. Sadoshima J., Aoki H., and Izumo S. Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Circulation Research 80 2 (1997) 228-241
23. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., Kitakaze M., and Liao J.K. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation 108 10 (2001) 1429-1437
24. Tamamori M., Ito H., Hiroe M., Terada Y., Marumo F., and Ikeda M.A. Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy. American Journal of Physiology 275 6 Pt 2 (1998) H2036-H2040
25. Tamamori-Adachi M., Ito H., Nobori K., Hayashida K., Kawauchi J., Adachi S., Ikeda M.A., and Kitajima S. Expression of cyclin D1 and CDK4 causes hypertrophic growth of cardiomyocytes in culture: a possible implication for cardiac hypertrophy. Biochemical and Biophysical Research Communications 296 2 (2002) 274-280
26. Tapon N., and Hall A. Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Current Opinion in Cell Biology 9 1 (1997) 86-92
27. Tse F.L., Jaffe J.M., and Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. Journal of Clinical Pharmacology 32 7 (1992) 630-638
28. Welsh C.F., Roovers K., Villanueva J., Liu Y., Schwartz M.A., and Assoian R.K. Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nature Cell Biology 3 11 (2001) 950-957
29. Zhang J.M., Zhao X., Wei Q., and Paterson B.M. Direct inhibition of G(1) cdk kinase activity by MyoD promotes myoblast cell cycle withdrawal and terminal differentiation. EMBO Journal 18 24 (1999) 6983-6993
30. Zhao Z., and Rivkees S.A. Rho-associated kinases play an essential role in cardiac morphogenesis and cardiomyocyte proliferation. Developmental Dynamics 226 1 (2003) 24-32